# To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

> **NCT04661007** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Biosciences Japan GK** · enrollment: 72 (actual)

## Conditions studied

- Non Hodgkins Lymphoma
- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** tafasitamab
- **DRUG:** lenalidomide
- **DRUG:** parsaclisib
- **DRUG:** R-CHOP

## Key facts

- **NCT ID:** NCT04661007
- **Lead sponsor:** Incyte Biosciences Japan GK
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-15
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04661007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04661007, "To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04661007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*